Page All:
Page 1
Medisafe 1 Technologies' Presentation on Company New Launched Website
JERUSALEM, November 5, 2010/PRNewswire-FirstCall/ --
- Demonstration can be Viewed Online at http://www.Medisafe1.com
Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented
technologies that physically prevent unauthorized administration of
prescription medications, announced today that the company has uploaded a
product presentation on the company's new website.
To view the website and the presentation, visit http://www.Medisafe1.com.
The presentation highlights the need for syringe locking device
technology, and illustrates how barcoding technology can help prevent
incorrect medications and dosages from being administered to a wrong patient
patient.
"Our online presentation appropriately demonstrates the potential harms
caused by human errors when incorrect medications are administered in
hospitals," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "The
presentation then demonstrates how MediSafe can prevent tragic mistakes from
taking place through the implementation of our patented worlds first syringe
locking-device technology."
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized
administration of a drug or medicinal substance by hypodermic needle.
Medisafe's patented technology is a medical assembly with a locking mechanism
that is intended to ensure the substance cannot be released from the
hypodermic needle without positive pre-matching between the substance and its
intended patient.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 as amended and Section 21E of the
Securities Exchange Act of 1934 as amended. All forward-looking statements
are inherently uncertain, based on current expectations and assumptions
concerning future events or future performance of Medisafe 1 Technologies
Corp., and its technologies. In evaluating such statements, prospective
investors should review carefully various risks and uncertainties identified
in this release, as actual results may differ materially from those
indicated. Medisafe 1 Technologies Corp. public filings may be viewed at
http://www.sec.gov.
Contact:
Jacob Elhadad
CEO
+972524440000
jacob.elhadad10@gmail.com
Source: Medisafe 1 Technologies Corp.
Contact: Jacob Elhadad, CEO, +972524440000, jacob.elhadad10@gmail.com .
Medisafe 1 Technologies' Presentation on Company New Launched Website
JERUSALEM, November 5, 2010/PRNewswire-FirstCall/ --
- Demonstration can be Viewed Online at http://www.Medisafe1.com
Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented
technologies that physically prevent unauthorized administration of
prescription medications, announced today that the company has uploaded a
product presentation on the company's new website.
To view the website and the presentation, visit http://www.Medisafe1.com.
The presentation highlights the need for syringe locking device
technology, and illustrates how barcoding technology can help prevent
incorrect medications and dosages from being administered to a wrong patient
patient.
"Our online presentation appropriately demonstrates the potential harms
caused by human errors when incorrect medications are administered in
hospitals," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "The
presentation then demonstrates how MediSafe can prevent tragic mistakes from
taking place through the implementation of our patented worlds first syringe
locking-device technology."
About Medisafe 1 Technologies
Medisafe 1 Technologies seeks to effectively prevent unauthorized
administration of a drug or medicinal substance by hypodermic needle.
Medisafe's patented technology is a medical assembly with a locking mechanism
that is intended to ensure the substance cannot be released from the
hypodermic needle without positive pre-matching between the substance and its
intended patient.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 as amended and Section 21E of the
Securities Exchange Act of 1934 as amended. All forward-looking statements
are inherently uncertain, based on current expectations and assumptions
concerning future events or future performance of Medisafe 1 Technologies
Corp., and its technologies. In evaluating such statements, prospective
investors should review carefully various risks and uncertainties identified
in this release, as actual results may differ materially from those
indicated. Medisafe 1 Technologies Corp. public filings may be viewed at
http://www.sec.gov.
Contact:
Jacob Elhadad
CEO
+972524440000
jacob.elhadad10@gmail.com
Source: Medisafe 1 Technologies Corp.
Contact: Jacob Elhadad, CEO, +972524440000, jacob.elhadad10@gmail.com .